This is an interesting if extended monologue from a lawyer about Pfizer’s most recent disclosure to the Stock Exchange Commission (SEC).
Though Pfizer has legal immunity v prosecution in the event it’s c19 “vaccine” harms people or doesn’t work (excepting fraud, which is notoriously difficult to prove), it has no such immunity if it misleads investors.
In order not to mislead investors, Pfizer must disclose material risks & uncertainties.
Surprisingly, in this latest SEC filing, they say “while our vaccine is currently subject to an emergency use authorization, our financial targets might suffer if we cannot demonstrate evidence of sufficient efficacy or safety to obtain formal, permanent regulatory approval”.
I’ve read a lot of SEC filings. They tend to be exhaustive. It’s always a risk that a product won’t gain an approval.
But this specific worry bead is surprising to anyone who doesn’t already know that is all data fraud.
Surely that ought to be a slam dunk after 15+ months of continuous use?
Best wishes
Mike



Channel: @RobinMG